The development of resistance to therapeutic agents represents a significant obstacle in the effective treatment of cancer. At the molecular level this drug-resistance is characterized by changes in signaling and gene expression that promote survival and proliferation, ultimately allowing progression to a more malignant phenotype. The long-term objective of this research is to understand the role of the MEK5-Erk5 signaling pathway in the tumorigenesis and resistance of breast carcinoma with the goal of developing targeting strategies for therapeutic intervention. Using gene expression profiling and examination of cell signaling we have identified and implicated the MEK5-Erk5 pathway as a critical component of acquired resistance coordinate to acquisition of an EMT and ER?-negative phenotype in breast cancer cells. Our preliminary data further suggests that MEK5-signaling functions through downstream transcription factors to mediate expression of EMT regulators (SLUG, ZEB1, ZEB2) and AKT3. Based upon this information we hypothesize that upregulation of MEK5-Erk5 signaling pathway induces the epithelial-to-mesenchymal transition, loss of ER? expression, and drives progression of breast cancer cells to a hormone-independent and therapeutically resistant phenotype. The proposed Specific Aims are designed to establish a role for MEK5 defining the specific mechanisms by which progression to a resistant phenotype occurs in vitro and in vivo.
Aim#1 : To test the hypothesis that Erk5 signaling is required for MEK5 -mediated breast cancer tumorigenesis and therapeutic resistance.
Aim#2 : To test the hypothesis that MEK5-Erk5 signaling functions in the progression to endocrine-independence and resistance through disruption of the ER?-signaling axis.
Aim#3 : To test the hypothesis that the MEK5-Erk5 signaling axis promotes an epithelial-to-mesenchymal transition, ER?-negative and invasive phenotype. In this proposal we expect to define and link a direct role the MEK5-Erk5 signaling pathway plays in the development of therapeutic resistance, and promotion of an aggressive phenotype in cancer cells. The establishment of this connection would define the MEK5-Erk5 pathway as potential molecular markers to be utilized as a prognostic indicator of therapeutic response and as a prospective molecular target for pharmacological drug development.

Public Health Relevance

While endocrine therapies, such as the anti-estrogen tamoxifen and the aromatase inhibitors, are important tools in the treatment of ER(+) breast carcinoma in the adjuvant and metastatic setting some tumors ultimately progresses to hormone-independence and resistance. Here we examine the role and mechanisms of the novel MEK5-Erk5 mitogen-activated protein kinase pathway in the regulation of cell survival and therapeutic resistance of breast cancer cells. We further examine the role of MEK5-Erk5 signaling in the progression of breast cancer cells to an ER?-negative and epithelial-to-mesenchymal transition phenotype. The research in this proposal is about understanding mechanisms of resistance and developing strategies to target and treat breast cancer progression.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Basic Mechanisms of Cancer Therapeutics Study Section (BMCT)
Program Officer
Forry, Suzanne L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Tulane University
Internal Medicine/Medicine
Schools of Medicine
New Orleans
United States
Zip Code
Matossian, Margarite D; Burks, Hope E; Elliott, Steven et al. (2018) Panobinostat suppresses the mesenchymal phenotype in a novel claudin-low triple negative patient-derived breast cancer model. Oncoscience 5:99-108
Matossian, Margarite D; Burks, Hope E; Bowles, Annie C et al. (2018) A novel patient-derived xenograft model for claudin-low triple-negative breast cancer. Breast Cancer Res Treat 169:381-390
Martin, Elizabeth C; Conger, Adrienne K; Yan, Thomas J et al. (2017) MicroRNA-335-5p and -3p synergize to inhibit estrogen receptor alpha expression and promote tamoxifen resistance. FEBS Lett 591:382-392
Hoang, Van T; Yan, Thomas J; Cavanaugh, Jane E et al. (2017) Oncogenic signaling of MEK5-ERK5. Cancer Lett 392:51-59
Anbalagan, Muralidharan; Sheng, Mei; Fleischer, Brian et al. (2017) Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ER?-negative Breast Cancers to Tamoxifen through ER? Reexpression. Mol Cancer Res 15:1491-1502
Conger, Adrienne K; Martin, Elizabeth C; Yan, Thomas J et al. (2016) Argonaute 2 Expression Correlates with a Luminal B Breast Cancer Subtype and Induces Estrogen Receptor Alpha Isoform Variation. Noncoding RNA 2:
Burks, Hope E; Phamduy, Theresa B; Azimi, Mohammad S et al. (2016) Laser Direct-Write Onto Live Tissues: A Novel Model for Studying Cancer Cell Migration. J Cell Physiol 231:2333-8
Phamduy, Theresa B; Sweat, Richard S; Azimi, Mohammad S et al. (2015) Printing cancer cells into intact microvascular networks: a model for investigating cancer cell dynamics during angiogenesis. Integr Biol (Camb) 7:1068-78
Miller, David F B; Yan, Pearlly X; Fang, Fang et al. (2015) Stranded Whole Transcriptome RNA-Seq for All RNA Types. Curr Protoc Hum Genet 84:11.14.1-23
Rhodes, Lyndsay V; Martin, Elizabeth C; Segar, H Chris et al. (2015) Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer. Oncotarget 6:16638-52

Showing the most recent 10 out of 40 publications